Qiagen stock heads into the open after a 1.0% Xetra gain
Published on 09/15/2026 at 08:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 14, 2026, Qiagen stock finished on Xetra at 36.91 euros, up 1.05% from the prior session, with the move leaving the shares above the mid point of their recent trading range. Compared with the German large cap benchmark, the gain meant Qiagen modestly outperformed the broader market on the day.
September 14, 2026 in numbers
Qiagen N.V. (ISIN NL0012169213) saw its Xetra-traded shares close at 36.91 euros on September 14, 2026, after opening the session close to that level and trading between an intraday low near 36.53 euros and an intraday high around 37.06 euros, according to Xetra data. The 1.05% advance against the prior Xetra close of 36.53 euros came on a reported turnover of just under 60,000 shares, indicating a moderate trading day for the stock. On the same date the main German equity benchmark index eased slightly, so the Qiagen move represented a relative gain versus the wider market.
As Aktiencheck.de reported on September 14, 2026, Morgan Stanley unexpectedly raised its price target for Qiagen and issued a buy signal on the shares, and the Xetra price reacted with a gain of about 0.36 euros or 0.99% to 36.89 euros at the time of that report. In parallel, Investing.com noted that Qiagen's new chief executive outlined strategic priorities at a Morgan Stanley conference, adding context to investor interest in the stock on the same day.
Events around today
Today, September 15, 2026, Qiagen does not have a widely reported scheduled event such as an earnings release or annual meeting, but the recent Morgan Stanley conference appearance and updated analyst view continue to frame sentiment into the open. Broader market attention remains on central bank policy and rates this week, and as CNBC highlighted on September 14, 2026, traders are watching rising interest rates and oil prices ahead of the Federal Reserve decision, factors that can influence risk appetite for European health care and diagnostics names such as Qiagen as the new session approaches.
